Adimab, a US-based drug developer of yeast-based antibodies previously backed by Google’s corporate venturing unit, raised $13.8m on Monday, according to a filing with the Securities and Exchange Commission.
Adimab said the series F round was raised entirely from existing investors. Adimab added the company had bought a 21,500 square foot research facility at 7 Lucent Drive in Lebanon, New Hampshire, as the company’s headquarters.
Adimab said it has collaborated on more than 20 antibody discovery projects in the last three years.
Adimab series E round raised $4m in November 2010, according to a regulatory filing. News provider Xconomy said the round was at a pre-money valuation of $520m with backing from all its previous investors that had provided less than $30m in aggregate across the A to E rounds.
Google Ventures led the D round in Adimab, with venture capital firms Borealis Ventures, OrbiMed Advisors, Polaris Venture Partners, and SV Life Sciences reinvesting.